Mustang Bio Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mustang Bio Inc.
ImmunoGen Antibody-Drug Conjugate Faces Delay After Study Split
Top-line results from the firm’s pivotal trial of pivekimab sunirine in a rare cancer indication have been delayed for two more years as the firm shifts focus to a specific subpopulation.
Mustang’s CAR-T MB-106 Shows Potential Competitiveness In CD20 Space
The company has maintained faith in autologous CAR-Ts, and its latest data show early signs of strong efficacy and favorable tolerability, possibly enabling outpatient use.
Finance Watch: Biopharma IPO Market Silence Continues In The US
Public Company Edition: The last biopharma IPO in the US was on 17 February and none have been scheduled, so far, for March. Also, another SPAC merger is called off, Travere sells $275m worth of notes and Xeris secures $150m in new debt, while Ovid, Passage Bio and others are cutting jobs.
Scrip Asks...What Does 2022 Hold For Biopharma? Part 3: Technology And Science
Many industry leaders expect broad progress in the field of RNA technologies following the rapid and successful roll-out of mRNA vaccines against COVID-19 last year. Genetic medicines of various types, emerging platforms for tackling previously “undruggable” targets and the microbiome were among other areas singled out as areas to watch in 2022.
- Gene Therapy, Cell Therapy
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.